We aspire to advance novel nanotechnology-based immunostimulatory agents for the treatment and prevention of cancer and infectious diseases
Mosaic IE is pioneering the development of nanoparticle-based immunotherapy that results in an individualized response to the patient's own cancer. Mosaic's lead candidate, MI-O-101, was carefully selected through years of research for its ability to act as an adjuvant that induces a robust local immune response. Once injected into the tumor, the local innate immune system immediately recognizes MI-O-101 due to its unique structural properties and RNA contained inside, which acts as a danger signal. The result is the stimulation of an enhanced local anti-tumor immune response that attacks the tumor resulting in an immune cascade that can eradicate the local tumor as well as distant sites of cancer spread known as the abscopal effect.
MI-O-101 has the potential to work alone or in combination with current standard of care, including chemotherapy, radiation, and immune checkpoint inhibitors. These candidates have broad therapeutic potential, including both human and veterinary applications. Data presented in over a dozen peer-reviewed publications since 2016 support the potential in many types of cancers, including melanoma, breast, ovarian, colon, and brain.
Modular Vaccine Platform (MVP)
Mosaic IE's MVP is based on combining the same nanotechnology based adjuvant used in immuno-oncology with carefully selected targets of interest to direct a protective or potentially a therapeutic immune response. This technology platform has been successfully evaluated for effectiveness in pre-clinical oncology studies and recently in infectious diseases including SARS-CoV-2 (COVID-19).
The MVP platform is designed to facilitate the rapid development vaccine candidates due to its modular nature. The adjuvant and linking chemistry can be stockpiled and ready for the rapid identification of targets of interest which can be linked for testing in a very short timeline.
The MVP platform combined with the company's proprietary delivery system which allows for self administration and shipment of materials at room temperature makes the platform ideal for rapid response situations.
Mosaic IE and its research partners are actively working toward finalizing a lead candidate for COVID-19 while simultaneously advancing the system for rapid response as well as the development of more traditional vaccine candidates in infectious diseases and oncology.
Plant Viruses as Nanotechnology
Platform based on CPMV nanotechnology (Core Development Molecule)
Nanotechnology involves the manipulation of structures and properties of matter at the nanoscale.
Nanomaterials and nanoparticles, resulting from the application of nanotechnology, offer the potential to change drug development.
Molecules and structures can be added to nanoparticles to develop new therapies and advanced drug delivery systems.
Using a single core base allows Mosaic IE to simultaneously move multiple therapeutic programs forward.
CPMV activates innate immune cells via Toll-like receptors (TLR) which recognize pathogen-associated molecular patterns (PAMPS).